<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41325">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02568397</url>
  </required_header>
  <id_info>
    <org_study_id>15997</org_study_id>
    <secondary_id>I8D-MC-AZEE</secondary_id>
    <nct_id>NCT02568397</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction Study of AZD3293 (LY3314814) in Healthy Participants</brief_title>
  <official_title>Effect of AZD3293 on the Pharmacokinetics of Dabigatran in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn about the effect of AZD3293 on how the body absorbs
      and processes dabigatran etexilate and how dabigatran etexilate affects AZD3293 when they
      are taken together. This study will last about 28 days and participants will be asked to
      take an AZD3293 tablet daily for 19 days and a dabigatran etexilate tablet on 3 occasions.
      Screening is required within 30 days prior to the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of Dabigatran</measure>
    <time_frame>Predose through 36 hours postdose on Days 1, 16 and 20 of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under The Dabigatran Pharmacokinetic (PK) Concentration Versus Time Curve from Zero to Infinity (AUC[0-infinity)</measure>
    <time_frame>Predose through 36 hours postdose on Days 1, 16 and 20 of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of AZD3293</measure>
    <time_frame>Predose through 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the AZD3293 Pharmacokinetic (PK) Concentration Versus Time Curve During One Dosing Interval (24 hours) (AUCtau)</measure>
    <time_frame>Predose through 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Area Under the Effect Versus Time Curve (AUEC) of Thrombin Time</measure>
    <time_frame>Predose through 36 hours postdose on Days 1, 16 and 20 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Ratio of Maximum Effect to Baseline Effect (ERmax) of Thrombin Time</measure>
    <time_frame>Predose through 36 hours postdose on Days 1, 16 and 20 of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran Etexilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of dabigatran etexilate administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD3293 + Dabigatran Etexilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD3293 administered orally once daily on Days 3 to 21. Single doses of dabigatran etexilate administered orally on 2 days during the AZD3293 dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Dabigatran Etexilate</arm_group_label>
    <arm_group_label>AZD3293 + Dabigatran Etexilate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3293</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>AZD3293 + Dabigatran Etexilate</arm_group_label>
    <other_name>LY3314814</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Overtly healthy males and females

        Exclusion Criteria:

          -  Eye abnormalities or disease

          -  History of vitiligo or any skin color disorder

          -  Have a history psychiatric or brain disease including seizures

          -  Have smoked within the last 3 months

          -  Are unwilling to avoid food and drinks containing grapefruit or Seville oranges for
             the duration of the study

          -  Have known allergies to dabigatran etexilate and related compounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 25, 2016</lastchanged_date>
  <firstreceived_date>October 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
